Crinetics Pharmaceuticals, Inc. — Director's Dealing 2021

Sep 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2021-09-07

Reporting Person: Struthers Richard Scott (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-07	Common stock	S	10000	$25.00	Disposed	90000	Indirect
2021-09-07	Common stock	S	10000	$25.00	Disposed	90000	Indirect
2021-09-07	Common stock	S	10000	$25.00	Disposed	90000	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock	1000	Indirect
Common stock	4000	Direct
Common stock	890805	Indirect

Footnotes

F1: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.